Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00131339 · ClinicalTrials.gov registry record · NA
Augmenting Exposure Therapy With an N-Methyl-D-Aspartate (NMDA) Agonist for Panic Disorder
A NA study, sponsored by Hartford Hospital.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT00131339 is a NA study that has completed, run by Hartford Hospital. The registered enrollment target is 40 participants.
The verdict
NCT00131339, a NA study, has completed, sponsored by Hartford Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study involves cognitive behavioral therapy (CBT) and a medication called D-cycloserine (DCS), which is thought to help reduce panic symptoms more effectively by interacting with N-methyl-D-aspartate (NMDA) glutamate receptors, facilitating many forms of learning including the extinction of fear. Participants will be randomly assigned (like flipping a coin) to receive either DCS or a placebo in addition to CBT.
Interventions
- DRUG D-cycloserine
- BEHAVIORAL Cognitive behavioral therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-11 |
| Est. Completion | 2007-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00131339
The ClinicalTrials.gov registry entry for NCT00131339 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hartford Hospital, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which D-cycloserine is the first listed.
NCT00131339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00131339 about?
NCT00131339 is a clinical study titled "Augmenting Exposure Therapy With an N-Methyl-D-Aspartate (NMDA) Agonist for Panic Disorder". This study involves cognitive behavioral therapy (CBT) and a medication called D-cycloserine (DCS), which is thought to help reduce panic symptoms more effectively by interacting with N-methyl-D-aspartate (NMDA) glutamate receptors, facilitating many forms of learning including the extinction of fea...
What is the current status of trial NCT00131339?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2004-11. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00131339?
The interventions under investigation include: D-cycloserine (DRUG), Cognitive behavioral therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00131339?
This trial is sponsored by Hartford Hospital, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.